Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, ANW, DB, FIZZ and REPH

TAL, ORA, PCG

NEW YORK, July 25, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

TAL Education Group (NYSE: TAL)
Class Period: April 26, 2018 to June 13, 2018
Lead Plaintiff Deadline: August 17, 2018

During the class period, TAL Education Group allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company overstated its net income; (2) the Company's net income was deteriorating; and (3) as a result of the foregoing, Defendants' statements about TAL's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the TAL lawsuit: http://www.kleinstocklaw.com/pslra-c/tal-education-group?wire=3.

Aegean Marine Petroleum Network Inc. (NYSE: ANW)
Class Period: April 28, 2016 to June 4, 2018
Lead Plaintiff Deadline: August 6, 2018

The complaint alleges that during the class period Aegean Marine Petroleum Network Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Aegean had improperly accounted for an approximate $200 million of accounts receivable as of December 31, 2017; (2) Aegean failed to maintain effective internal control over financial reporting; and (3) as a result of the foregoing, Defendants’ statements about Aegean’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.   

Get additional information about the ANW lawsuit: http://www.kleinstocklaw.com/pslra-c/aegean-marine-petroleum-network-inc?wire=3.

Deutsche Bank Aktiengesellschaft (NYSE: DB)
Class Period: March 20, 2017 to May 30, 2018
Lead Plaintiff Deadline: August 6, 2018

The lawsuit alleges Deutsche Bank Aktiengesellschaft made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Deutsche Bank's internal control environment and infrastructure were materially weak and deficient; and (2) as a result, Deutsche Bank's statements about the Company's business and operations were materially false and misleading at all relevant times.    

On May 31, 2018, The Wall Street Journal reported that the U.S. Federal Reserve had designated Deutsche Bank’s U.S. business as being in a “trouble condition,” citing concerns about “its controls around measuring financial exposure to clients and valuing collateral that backed loans.” It was also reported that the Federal Deposit Insurance Corporation (“FDIC”) added Deutsche Bank’s FDIC-insured subsidiary, Deutsche Bank Trust Company Americas, to a list of “problem banks” which are at-risk. On this news, Deutsche Bank’s share price fell $0.49 or over 4% to close at $11.08 on May 31, 2018. 

Get additional information about the DB lawsuit: http://www.kleinstocklaw.com/pslra-c/deutsche-bank-aktiengesellschaft-2?wire=3.

National Beverage Corp.  (NASDAQ: FIZZ)
Class Period: July 17, 2014 to July 3, 2018
Lead Plaintiff Deadline: September 17, 2018

The complaint alleges that throughout the class period National Beverage Corp.  made materially false and/or misleading statements and/or failed to disclose that: (1) National Beverage's sales claims and its supposed "proprietary techniques" lacked a verifiable basis; (2) the Company's Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage's public statements were materially false and misleading at all relevant times.    

On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).”  National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage's CEO had sexually harassed them. 

Get additional information about the FIZZ lawsuit: http://www.kleinstocklaw.com/pslra-c/national-beverage-corp?wire=3.

Recro Pharma, Inc. (NASDAQ: REPH)
Class Period: July 31, 2017 to May 23, 2018
Lead Plaintiff Deadline: July 30, 2018

According to the complaint, Recro Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration ("FDA") approval; and (2) as a result, Recro Pharma's public statements were materially false and misleading at all relevant times. On May 24, 2018, Recro Pharma announced that the FDA had declined to approve its New Drug Application ("NDA") for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug's analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.

Get additional information about the REPH lawsuit: http://www.kleinstocklaw.com/pslra-c/recro-pharma-inc-2?wire=3.

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Primary Logo